MPMichael J. Parks

Michael J. Parks

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael J. Parks has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluating the Generalizability of Substance Use Treatment Outcomes at One-Month Follow-Ups Using Data From a Random Sample of Discharged Patients at a Single US-Based Treatment Center

    by Quyen M. Ngo, Jermaine D. Jones, Paulette Baukol, Kaitlyn Mishlen, Tara Cantwell, Michael J. Parks

    There is a dearth of research that evaluates the generalizability of substance use disorder treatment outcomes. We assess one-month follow-up survey results and evaluate generalizability of outcomes for individuals randomly selected after discharge from a non-profit treatment center. The sample consisted of discharged patients (N = 6771). Follow-up measures were: alcohol/drug abstinence, self-reported health, quality of life, peer-recovery group attendance, follow-up treatment receipt, medication use, and craving. Descriptive and logistic regression analyses compared patients who were randomly selected to those not selected, and follow-up respondents to non-respondents; 10 measures (demographic, treatment- and diagnosis-related measures) were used to assess selection and nonresponse. A survey weight was generated that accounted for selection, and response/attrition. Outcomes were estimated using weights, and these estimates were compared to unweighted values. Weighted abstinence rate one month after treatment was 76.4% (95% CI = 74.4%, 78.4%); unweighted rate was 78.2% (95% CI = 76.4%, 79.9%). Eight out of the 10 measures used to assess survey response significantly predicted response. All 6 outcome measures were statistically similar across weighted and unweighted analyses. One-month follow-up results were representative of daily discharged population at a single US-based treatment center. Centers should use sampling designs that ensure generalizability and provide full methodological details when reporting follow-up measures.

  • The Effects of State-Level Flavored Electronic Cigarette Restrictions on Adult Tobacco Use Using Multilevel Modeling: Findings From the PATH Study Waves 5 and 7 (2018–2023)

    by John H Kingsbury, Michael J Parks, Heather L Kimmel, Eiman Aboaziza, Carlos Blanco, Wilson M Compton

    Introduction: Flavors play an important role in e-cigarette use among both young people and adults, but evaluations of flavored e-cigarette policies have focused almost exclusively on youth. This longitudinal study examined how flavored e-cigarette policies affect tobacco use over time for different adult age groups using data from the Population Assessment of Tobacco and Health (PATH) Study. Methods: Adults aged 21 or above at Wave 5 (2018–2019) comprised the analytic sample. Multilevel models were used to examine changes in past 30-day and established e-cigarette use, and past 30-day tobacco use other than e-cigarettes at Wave 7 (2022–2023) for residents of states that had (vs had not) implemented flavored e-cigarette policies between Waves 5 and 7. Sociodemographic variables and state-level tobacco control policies (eg, e-cigarette tax, clean indoor air) were controlled. Regression models tested effects overall and by age group: 21–24, 25–29, 30–39, 40, or above. Full-sample and replicate weights accounted for the complex sample design and nonresponse. Results: Among those exposed to a flavored e-cigarette policy, there was a significant decrease in odds of past 30-day e-cigarette use for those age 21–24 (AOR = 0.59; 95% CI: 0.36, 0.97) and in odds of established e-cigarette use for those age 25–29 (AOR = 0.32; 95% CI: 0.14, 0.76) compared to those who were unexposed, adjusting for covariates. There was no change in use of tobacco products other than e-cigarettes by flavored policy exposure. Conclusions: Flavored e-cigarette policies are effective at reducing past 30-day and established e-cigarette use among younger adults (aged 21–29). The impact among older adults (30 or above) is less evident. Implications: Using longitudinal data and multilevel models, this study demonstrates how flavored e-cigarette policies influence e-cigarette use (and other tobacco product use) for younger adults (21–29). We find limited evidence of policies influencing older adults (30 or above). This work suggests that flavored e-cigarette policies may play an important role in stopping young people from initiating e-cigarette use, and in stopping older young adults who are 25–29 from progressing to more established e-cigarette use.


  • Open Access

    United States trends in non‐prescribed use of Adderall and Ritalin: Population Assessment of Tobacco and Health (PATH) Study estimates from 2013 to 2022

    by Joshua P. Rising, Michael J. Parks, Beth Han, Rose Radin, Celeste Mallama, Heather L. Kimmel, MeLisa R. Creamer, Wilson M. Compton

    Background and Aims: Dispensing of prescription stimulants to adults has risen dramatically over the past decade. Examining trends in nonprescribed use of prescription stimulants can inform public health responses. Most studies in the United States (U.S.) have faced challenges in assessing trends over time due to changes in survey methodologies and variation in populations assessed. We examined data from the Population Assessment of Tobacco and Health (PATH) Study to assess changes in nonprescribed use of prescription stimulants in the U.S. from 2013 to 2022.Design: The PATH Study is an ongoing longitudinal study of U.S. youth and adults, representative of the civilian noninstitutionalized population. Repeated cross‐sectional estimates at each wave were used (8 total waves). Trends from Wave (W) 1 (September 2013–December 2014) to W7 (January 2022–April 2023) were assessed. Full‐sample and replicate weights were used; joinpoint analyses and wave‐to‐wave comparisons were applied to test trends.Setting: Civilian noninstitutionalized U.S. youth and adults.Participants/Cases: Youth aged 12–17 and adults aged 18 + were assessed, with a total of 45 727 participants at wave 1 (Ns vary by wave).Measurements: Past 12‐month (P12M) prevalence of nonprescribed use of Ritalin or Adderall was assessed. Nonprescribed use of stimulants was assessed across subgroups according to age (12–17, 18–24, 25–39, ≥40) and sex (male, female).Findings: While wave‐to‐wave comparisons showed fluctuations across certain waves, overall, there were no statistically significant changes in P12M prevalence of Ritalin or Adderall nonprescribed use (1.3% at W1 and 1.5% at W7) across the study period. However, statistically significant differences in trends existed across age groups. Among 12–17 year‐olds, nonprescribed use prevalence remained stable (1.4% in W1 and 1.5% in W7). Nonprescribed use prevalence also remained stable for 18–24‐year‐olds from W1 to W3, but then significantly declined (p = 0.016) from W3 (5.3%) to W7 (2.6%). There were no significant changes in nonprescribed use prevalence among 25–39‐year‐olds (1.7% in W1 and 2.4% in W7) and those aged ≥40 (0.3% in W1 and 0.9% in W7). Across most waves, young adults aged 18–24 had a statistically significantly higher prevalence of nonprescribed use. Neither sex had significant trends in P12M nonprescribed use prevalence.Conclusions: Despite an increase in dispensing of prescription stimulant medications in the United States, the prevalence of nonprescribed Ritalin or Adderall use does not appear to have increased, as assessed in the nationally representative Population Assessment of Tobacco and Health (PATH) Study. The prevalence of nonprescribed Ritalin or Adderall use among young adults aged 18–24, the age group with the highest nonprescribed use prevalence, declined 2013 to 2022.


  • Vaping-Specific Nicotine Dependence Across Days Among a National Sample of US Young Adults Who Vape

    by Michael J Parks, Brooke J Arterberry, Megan E Patrick

    Introduction: Vaping has increased among young adults (YAs), and nicotine dependence prevalence has increased among YAs who vape, in the US. Research on nicotine dependence symptoms (NDS) among YAs who vape remains limited, and accurately measuring NDS and their severity remains a challenge. To date, no research has considered day-to-day NDS, as previous research focuses on retrospective measures. Aims and Methods: Daily data came from the Monitoring the Future Vaping Supplement; out of 1244 YAs, we analyzed data from 150 (Mage = 19 [SE = 0.44]; 71.2% non-Hispanic white; 57.8% male) who vaped nicotine at least once during 14 daily surveys (n = 882 nicotine vaping days). The vaping-specific Hooked on Nicotine Checklist measured NDS on nicotine vaping days. Dichotomous and count measures of NDS were used at the day level and aggregated to the person level. Descriptive analyses and multilevel regression models were used. Weights ensured generalizability and adjusted for attrition. Results: Any NDS were reported on 64.5% of nicotine vaping days (average 1.93 symptoms); 43.3% of nicotine vaping days had more than 1 NDS. Results across persons (rather than days) showed any NDS on 53.8% of nicotine vaping days, and 45.4% YAs reported between 1 and 2 symptoms per vaping day; 23.3% reported 2 + symptoms on average. Multilevel models showed nontrivial variance across days and persons in NDS, and regular vaping at baseline predicted NDS. Conclusions: Vaping-specific NDS varied across days and persons for any NDS and NDS severity. Future research should consider daily NDS fluctuations, identifying factors that confer risk to inform NDS prevention and treatment among YAs who vape. Implications: NDS and its severity varied across days and persons, demonstrating the utility of daily data. The results were generally similar for experiencing any NDS and NDS severity, but there was slightly more variability across days for any NDS. Intervention and treatment strategies could utilize approaches that identify and address daily symptoms to help curb nicotine dependence. Future research and treatment efforts should also consider the immediate contexts and potential factors that explain particularly elevated NDS on a given day.


  • Open Access

    Association Between Clinician-Level Factors and Patient Outcomes in Virtual and In-Person Outpatient Treatment for Substance Use Disorders: Multilevel Analysis

    by Justine W Welsh, Siara I Sitar, Michael J Parks, Samantha C Patton, Jacqueline E Braughton, Lance A Waller, Quyen M Ngo

    Background: The use of virtual treatment services increased dramatically during the COVID-19 pandemic. Unfortunately, large-scale research on virtual treatment for substance use disorder (SUD), including factors that may influence outcomes, has not advanced with the rapidly changing landscape. Objective: This study aims to evaluate the link between clinician-level factors and patient outcomes in populations receiving virtual and in-person intensive outpatient services. Methods: Data came from patients (n=1410) treated in a virtual intensive outpatient program (VIOP) and an in-person intensive outpatient program (IOP), who were discharged between January 2020 and March 2021 from a national treatment organization. Patient data were nested by treatment providers (n=58) examining associations with no-shows and discharge with staff approval. Empathy, comfort with technology, perceived stress, resistance to change, and demographic covariates were examined at the clinician level. Results: The VIOP (β=–5.71; P=.03) and the personal distress subscale measure (β=–6.31; P=.003) were negatively associated with the percentage of no-shows. The VIOP was positively associated with discharges with staff approval (odds ratio [OR] 2.38, 95% CI 1.50-3.76). Clinician scores on perspective taking (β=–9.22; P=.02), personal distress (β=–9.44; P=.02), and male clinician gender (β=–6.43; P=.04) were negatively associated with in-person no-shows. Patient load was positively associated with discharge with staff approval (OR 1.04, 95% CI 1.02-1.06). Conclusions: Overall, patients in the VIOP had fewer no-shows and a higher rate of successful discharge. Few clinician-level characteristics were significantly associated with patient outcomes. Further research is necessary to understand the relationships among factors such as clinician gender, patient load, personal distress, and patient retention.


  • Open Access

    Association Between Clinician-Level Factors and Patient Outcomes in Virtual and In-Person Outpatient Treatment for Substance Use Disorders: Multilevel Analysis (Preprint)

    by Justine W Welsh, Siara I Sitar, Michael J Parks, Samantha C Patton, Jacqueline E Braughton, Lance A Waller, Quyen M Ngo

    BACKGROUND The use of virtual treatment services increased dramatically during the COVID-19 pandemic. Unfortunately, large-scale research on virtual treatment for substance use disorder (SUD), including factors that may influence outcomes, has not advanced with the rapidly changing landscape. OBJECTIVE This study aims to evaluate the link between clinician-level factors and patient outcomes in populations receiving virtual and in-person intensive outpatient services. METHODS Data came from patients (n=1410) treated in a virtual intensive outpatient program (VIOP) and an in-person intensive outpatient program (IOP), who were discharged between January 2020 and March 2021 from a national treatment organization. Patient data were nested by treatment providers (n=58) examining associations with no-shows and discharge with staff approval. Empathy, comfort with technology, perceived stress, resistance to change, and demographic covariates were examined at the clinician level. RESULTS The VIOP (β=–5.71; P=.03) and the personal distress subscale measure (β=–6.31; P=.003) were negatively associated with the percentage of no-shows. The VIOP was positively associated with discharges with staff approval (odds ratio [OR] 2.38, 95% CI 1.50-3.76). Clinician scores on perspective taking (β=–9.22; P=.02), personal distress (β=–9.44; P=.02), and male clinician gender (β=–6.43; P=.04) were negatively associated with in-person no-shows. Patient load was positively associated with discharge with staff approval (OR 1.04, 95% CI 1.02-1.06). CONCLUSIONS Overall, patients in the VIOP had fewer no-shows and a higher rate of successful discharge. Few clinician-level characteristics were significantly associated with patient outcomes. Further research is necessary to understand the relationships among factors such as clinician gender, patient load, personal distress, and patient retention. CLINICALTRIAL

  • 140 The intersection of depressive symptoms, adverse childhood experiences, and protective factors among adolescents: epidemiological evidence from Minnesota, 2016 and 2019

    by Michael J. Parks, Jon Roesler, Beatriz Menanteau, Marissa Raguet, Marla E. Eisenberg

    Prevalence of mental health problems among US youth has increased in recent years, and there is a dearth of epidemiological research at the state level tha